Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Accounts Payables: 2010-2025

Historic Accounts Payables for China Pharma Holdings (CPHI) over the last 14 years, with Sep 2025 value amounting to $2.3 million.

  • China Pharma Holdings' Accounts Payables rose 37.20% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 37.20%. This contributed to the annual value of $2.2 million for FY2024, which is 4.37% down from last year.
  • Per China Pharma Holdings' latest filing, its Accounts Payables stood at $2.3 million for Q3 2025, which was down 1.78% from $2.3 million recorded in Q2 2025.
  • China Pharma Holdings' Accounts Payables' 5-year high stood at $3.1 million during Q2 2021, with a 5-year trough of $1.6 million in Q2 2024.
  • In the last 3 years, China Pharma Holdings' Accounts Payables had a median value of $2.2 million in 2023 and averaged $2.1 million.
  • Within the past 5 years, the most significant YoY rise in China Pharma Holdings' Accounts Payables was 668.19% (2021), while the steepest drop was 50.25% (2021).
  • Quarterly analysis of 5 years shows China Pharma Holdings' Accounts Payables stood at $1.9 million in 2021, then rose by 26.85% to $2.4 million in 2022, then decreased by 4.49% to $2.3 million in 2023, then fell by 4.37% to $2.2 million in 2024, then surged by 37.20% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $2.3 million for Q2 2025, and $2.2 million during Q1 2025.